BioLife Solutions, Inc. (BLFS)
| Market Cap | 1.52B +53.7% |
| Revenue (ttm) | 101.66M +29.9% |
| Net Income | -2.96M |
| EPS | -0.07 |
| Shares Out | 48.86M |
| PE Ratio | n/a |
| Forward PE | 136.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,741,998 |
| Open | 29.68 |
| Previous Close | 29.19 |
| Day's Range | 29.65 - 31.49 |
| 52-Week Range | 17.86 - 31.47 |
| Beta | 1.94 |
| Analysts | Strong Buy |
| Price Target | 31.89 (+2.33%) |
| Earnings Date | Aug 6, 2026 |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc... [Read more]
Financial Performance
In 2025, BioLife Solutions's revenue was $96.21 million, an increase of 28.89% compared to the previous year's $74.65 million. Losses were -$4.60 million, -77.23% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price target is $31.89, which is an increase of 2.33% from the latest price.
News
BioLife Solutions downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded BioLife Solutions (BLFS) to Hold from Buy with a $31 price target after Repligen (RGEN) announced a definitive agreement to acquire the company for $31 per share. Published…
BioLife Solutions downgraded to Hold from Buy at Maxim
Maxim downgraded BioLife Solutions (BLFS) to Hold from Buy after Repligen (RGEN) announced a definitive agreement to acquire the company for $31 per share.
BioLife Solutions downgraded to Hold from Buy at Lake Street
Lake Street downgraded BioLife Solutions (BLFS) to Hold from Buy with a price target of $31, down from $33, after Repligen (RGEN) announced a definitive agreement to acquire the company…
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing ce...
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
06:01 EDT Repligen (RGEN) to acquire BioLife Solutions (BLFS) for $31 per share, or $1.5B
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
Repligen (RGEN) and BioLife Solutions (BLFS) announced they have entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total ent...
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business
Biolife attracts takeover interest from Repligen, Bloomberg says
Biolife Solutions (BLFS) has drawn takeover interest from several parties, including Repligen (RGEN), Bloomberg’s Dinesh Nair and Michelle F. Davis report, citing people with knowledge of the matter. ...
BioLife Solutions Slides: Investor presentation
BioLife Solutions has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
BioLife Solutions reports Q1 EPS 2c, consensus 2c
Reports Q1 revenue $27.5M, consensus $25.66M. “We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million,” said CEO Roderick de…
BioLife Solutions sees 2026 revenue $112.5M-$115.0M, consensus $112.94M
16:22 EDT BioLife Solutions (BLFS) sees 2026 revenue $112.5M-$115.0M, consensus $112.94M
BioLife Solutions Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 25% year-over-year to $27.5M, led by BPM demand, with adjusted EBITDA up 15%. Guidance for 2026 revenue of $112.5–$115M and margin expansion was reaffirmed, as operational improvements and new product launches are expected to drive growth.
BioLife Solutions Earnings release: Q1 2026
BioLife Solutions released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
BioLife Solutions Quarterly report: Q1 2026
BioLife Solutions has published its Q1 2026 quarterly earnings report on May 7, 2026.
BioLife Solutions Reports First Quarter 2026 Financial Results
Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of r...
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar...
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading develop...
BioLife Solutions management to meet virtually with Northland
Virtual Meeting to be held on April 8 at 10 am hosted by Northland.
BioLife Solutions pullback creates buying opportunity, says Northland
Northland analyst Carl Byrnes reiterates BioLife Solutions (BLFS) as a “Top Pick 2026” and views the recent pullback as “a compelling buying opportunity” given improving fundamentals and its re-establ...
BioLife Solutions Slides: Investor presentation
BioLife Solutions has posted slides in relation to its latest quarterly earnings report, which was published on February 27, 2026.
BioLife Solutions Earnings Call Transcript: Q4 2025
Delivered 29% revenue growth and margin expansion in 2025, driven by commercial BPM customers and portfolio optimization. 2026 guidance calls for 17–20% revenue growth, positive GAAP net income, and continued margin improvement, with growth led by commercial demand.
BioLife Solutions Annual report: Q4 2025
BioLife Solutions has published its Q4 2025 annual report on February 26, 2026.
BioLife Solutions Earnings release: Q4 2025
BioLife Solutions released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
BioLife Solutions reports Q4 EPS 4c vs. (3c) last year
Reports Q4 revenue $24.8M, consensus $24.01M. “2025 was a transformative year for BioLife. We delivered 29% revenue growth, led by sustained strength in our biopreservation media franchise and complet...
BioLife Solutions sees 2026 revenue $112.5M-$115.0M, consensus $110.75M
Sees 2026 gross margin in the mid-60% range and continued expansion of adjusted EBITDA margin.